Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Sanofi

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Sanofi's 2013 sales performance.

Sanofi

FDA issues approval for Sanofi’s Enjaymo treatment for patients with CAD

FDA issues approval for Sanofi’s Enjaymo treatment for patients with CAD The US FDA has approved Sanofi’s Enjaymo (sutimlimab-jome) for the treatment of adults diagnosed with the rare blood disorder, cold agglutinin disease (CAD). ... Bill Sibold, Sanofi’s executive vice president and head of Specialty Care said: “Until

Sanofi unveils new corporate brand and logo

Sanofi unveils new corporate brand and logo Sanofi has unveiled its new corporate brand image, which reflects the organisation’s ongoing transformation and modernisation. ... Looking ahead, Sanofi aims to continue with its goals of providing healthcare innovation and furthering its company

Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results

Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results The latest news from Sanofi Genzyme and Regeneron Pharmaceuticals shared positive results from the second phase 3 for Dupixent (dupilumab), a medicine the companies developed to target chronic inflammatory skin diseases. ... Dupixent is a jointly

Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies

Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies According to the terms detailed in the agreement, Sanofi will pay Exscientia an upfront cash payment of $100m. ... Alongside this, Sanofi will take responsibility for preclinical and clinical development, manufacturing and further commercialisation.

FDA rejects Takeda’s Eohilia after delays

FDA rejects Takeda’s Eohilia after delays The rejection by the FDA potentially clears the way for Sanofi’s Dupixent (dupilumab), which received breakthrough therapy designation in EoE back in September 2020. ... In October 2021, Sanofi announced results of a second phase 3 trial for Dupixent

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...